



Figure S4. Carboplatin resistance potentiated by ABCB1 inhibitor tariquidar in RB006. **(A)** Carboplatin challenge of RB006 and RB028^{Naive} over one week. **(B)** Representative kill curve at Hour 140 for carboplatin challenge demonstrates greater carboplatin resistance for RB006 compared to RB028^{Naive} (EC_{50} for RB028^{Naive} ~2.26 μ M; EC_{50} for RB006 ~39.04 μ M). **(C)** Normalized viability of RB006 cells monitored over 1 week after challenge with carboplatin (1 μ M) along with tariquidar (4 μ M). **(D)** Normalized viability of RB006 cells at the 150 hour time point from panel C for the indicated treatment groups (Bliss score = 41.0%, observed inhibition = 55.8%, excess over Bliss score = 13.8%). **(E)** 3D synergy map of RB006 using Bliss scores.